Navigation Links
BIT C2 Diagnostics Adds Hematology Competence Center
Date:1/29/2013

Irvine, CA (PRWEB) January 29, 2013

BIT C2 Diagnostics, a BIT company located in Montpellier, France, has announced immediate expansion of its 1400 square meter facility to include a Hematology Competence Center. Construction of the 2.7 million Euro, 400 square meter expansion is already complete and occupation of the new Center is expected by the end of January, 2013. “We’re looking forward to having the space to work on more projects simultaneously,” said Eric Jolain, CEO of BIT C2 Diagnostics. “We’ll also be able to ensure greater reliability at product launch due to the fact that all production will now be done internally, interfacing strictly with other BIT manufacturing sites – such as BIT Analytical Instruments, GmbH and BIT MedTech in Irvine, CA, USA.”

BIT C2 Diagnostics is a leader in development, design, manufacture and support of custom Hematology instrumentation. With its comprehensive technical expertise, BIT C2 Diagnostics is able to provide a large array of engineering services, from rapid prototyping to OEM design and manufacturing.

BIT C2 Diagnostics is a BIT company. For over 35 years BIT Group has provided services in the field of contract development and manufacturing as well as after-sales service for customers in the fields of medical, diagnostics, life science, and biotechnology. As a part of the financially strong Messer Group, BIT Companies provide their systems solutions worldwide and in compliance with ISO 13485 and 9001 standards. As registered contract service providers to the FDA, BIT Companies meet the stringent regulations with regard to medical and complex medical technical products while simultaneously adhering to predefined design-to-cost and time-to-market targets.

BIT Companies include BIT Medtech, Source Scientific, & BIT Analytical Instruments Ltd. (USA) BIT Analytical Instruments GmbH (Germany); BIT Technologies (China); BIT Japan (Japan); and BIT C2 Diagnostics (France).

Read the full story at http://www.prweb.com/releases/2013/1/prweb10367541.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Advanced Cell Diagnostics Appoints Evangeline Gonzalez as Chief Commercial Officer
2. SeraCare Life Sciences Sharpens Focus on Diagnostics Industry
3. Major Diabetes Peer-Review Journal Publishes Postive Results Of Ultradian Diagnostics Human Pilot Study
4. PharmSource Lead Sheet Adds Coverage of Medical Devices and Diagnostics
5. RiboMed Receives Three Additional Patents for Disease Diagnostics Methods
6. RiboMed Receives Three Additional Patents for Disease Diagnostics Methods
7. Quest Diagnostics Clinical Trials Biorepository Accredited by the College of American Pathologists
8. MiMedx Group to Present at the Canaccord Genuity Medical Technology & Diagnostics Forum
9. Aushon BioSystems and AH diagnostics unterzeichnen Distributionsvertrag für Skandinavien
10. Aushon BioSystems and AH diagnostics Sign Distribution Deal for Scandinavia
11. Advanced Cell Diagnostics Completes $12 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... ... April 27, 2016 , ... Cambridge Semantics, the leading provider of ... that it has been named to The Silicon Review’s “20 Fastest Growing Big Data ... Cambridge Semantics serves the needs of end users facing some of the most complex ...
(Date:4/27/2016)... ... ... The Pittcon Organizing Committee is pleased to announce that Charles “Chuck” Gardner was ... since 1987. Since then, he has served in a number of key leadership positions ... the program and exposition committees. In his professional career, Dr. Gardner is the director ...
(Date:4/27/2016)... 27, 2016 NanoStruck Technologies ... NSKQB) ( Frankfurt : 8NSK) gibt ... vom 13. August 2015 die Genehmigung von der ... zusätzliche 200.000.000 Einheiten auf 400.000.000 Einheiten zu erhöhen, ... Davon wurden 157.900.000 Einheiten mit dem ersten Teil ...
(Date:4/27/2016)... ... April 27, 2016 , ... The Board ... the appointment of John Tilton as Chief Commercial Officer.  Mr. Tilton joined Biohaven ... the founding commercial leaders responsible for the commercialization of multiple orphan drug indications. ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted to ... of 2015 The gross margin was 49% (27) ... operating margin was 40% (-13) Earnings per share rose ... was SEK 249.9 M (21.2) , Outlook   ... The operating margin for 2016 is estimated to exceed ...
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
(Date:3/29/2016)... Florida , March 29, 2016 ... the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased ... in ink used in a variety of writing instruments, ... Buyers of originally created collectibles from athletes on LegacyXChange ... forensic analysis of the DNA. Bill ...
Breaking Biology News(10 mins):